CONFERENCE MEDIA ANALYSIS January 2018 · 22 CONFERENCEMEDIAANALYSIS| January6 - 16, 2018 4...

11

CONFERENCE MEDIA ANALYSISJanuary 2018

22

C O N F E R E N C E M E D I A A N A L Y S I S | J a n u a r y 6 - 1 6 , 2 0 1 8

4 Executive Summary

7 Conference Media Analysis

12 Merck at JPM18 Overview

News Media Performance

Social Media Performance

News Media Coverage by Topic

Other Notable Conference Themes

17 Methodology Detail

News Media Performance

Social Media Performance

Quality of Coverage

3 Report Objective & Methodology

Influencers

Spotlight on Neuroscience

33


PrefaceJ.P. Morgan held its 36th Annual Healthcare Conference (the “Conference or JPM18”) on January 8-11, 2018. Cision, and itsanalytics and information services division, Cision Intelligence, sought to understand the major media stories generated duringthe conference, the volume and quality of news and social media related to those storylines, and the companies and speakersproducing the greatest media reach and engagement. This report is an independent research initiative completed by Cision,based solely on its software-based monitoring of broadcast, online, and social media where stories, companies, and speakersparticipating in the conference were identified. Although no participant, nor J.P. Morgan sponsored nor endorsed this work, weshowcased Merck to highlight a deeper company-specific review. Cision retains all rights to this material.

Scope & MethodologyAlthough the Conference was held January 8-11, we monitored broadcast and online news, as well as social media from January6-16, 2018. We filtered the monitoring to approximately 120 major national, regional, and investor-focused outlets. And, becauseTwitter was the most dominant social channel, we excluded activity on other social platforms as non-material. We monitoredmedia activity for 22 pharmaceutical companies, yet limited the report analysis to nine (9) companies with the greatest activity,namely Allergan, Celgene, Eli Lilly, GSK, J&J, Merck, Pfizer, Sanofi, and Teva.

For each relevant story and company, we human-scored multiple attributes as quantitative proxies for quality, such assentiment/tone (on a proprietary 7-point scale from very negative to very positive), prominence within the article, quotedexecutives, references to innovation, and references to financial announcements or commentary.

The team assembled the raw data to then understand comparative story count volumes; audience reach (actual views based onadvanced machine learning algorithms); social volume and news article engagement on social media; the most influentialjournalists and outlets based on reach and end-reader engagement; and share-of-voice (SOV) across many of these metrics andstory quality attributes, such as tone.

Lastly, we highlight our Quality Score, a weighted brand reputation index that reflects a weighted score across relevant storyattributes; the higher the Quality Score, the more impactful the story. See slide 18 for additional information about ourmethodology.

44


Executive Summary – JPM18 Highlights

• Tax Reform was a timely and significant theme for the meeting. Coverage emphasized that the new policy is good for the pharmaceutical business, while other coverage questioned whether it’s good for patients.

• In advance of the conference, Pfizer’s exit from Alzheimer’s/Parkinson’s R&D was widely covered, and media followed up with other industry leaders to get their perspectives. Overall, the industry is portrayed as remaining committed to research in that area moving forward.

• Drug Pricing was discussed in coverage about tax reform, but also in coverage of competitiveness in the pharma industry, and interviews with pharma executives.

• Other themes included gender inequity in the pharmaceutical industry, the need for industry disruption, and Bill Gates’ keynote.

Major Story Lines

55


Executive Summary - Competitive Performance

Share of Story Count Share of Social Posts Share of News Engagement

• J&J led share of voice in news and social mentions overall, though saw the lowest share of stories with a primary focus during the conference. Much of the social conversation was driven by owned content.

• Pfizer led among stories with a primary focus and saw the highest number of news story shares to social media, though this was largely due to a high percentage of negative coverage.

• GSK and Celgene followed Pfizer in terms of primary coverage, respectively, though GSK’s primary coverage was far more favorable than Celgene’s. Celgene followed J&J in social post volume.

• Merck ranked 6th among companies tracked at JPM18 in terms of story count overall, 7th for stories with a primary focus, and 5th in social media content.

66


Post Count by Day

Executive Summary – Daily News + Social Drivers

Pfizer: Pulling Out of Alzheimer’s/Parkinso

n’s

Merck: Thought Leadership on Drug Pricing, Alzheimer’s

Story Count by DayCelgene: Impact $7B

Acquisition

Teva: Executive Salary Cuts, and Layoffs

GSK: Considering Buying Pfizer’s Consumer Business

Allergan: Financial Forecast

J&J: #ChampionsOfScien

ce RTsMerck: Maria Bartiromo/Fox Business Interview with CEO

Ken Frazier

Celgene: Intent to Acquire Impact

Biomedicines

Pfizer: Announcement of New Genetic

Sequencing Consortium

Eli Lilly: Surpassed Merck in Revenue; Diabetes Pricing

77


Competitive News Media PerformanceStory Volume Comparison

Company StoryCount Audience % Primary % Pos % Neg Share Eng Share of

JPM18* Highlights

Merck 70 3.6M 11% 83% 0% 6K 10%Merck CEO Kenneth Frazier commenting on the tax overhaul’s impact on

the pharmaceutical industry, drug pricing, and Alzheimer’s research drove coverage.

Pfizer 114 5.9M 49% 59% 30% 193K 16%GSK’s interest in purchasing Pfizer’s Consumer Business and pulling out of Alzheimer’s research contributed to a peak in coverage on January 8

and 9.

Allergan 44 1.6M 27% 73% 5% 174K 9% CEO Brent Saunders touted the company’s booming Botox business and discussed the company’s 2018 financial forecast during JPM18.

Eli Lilly 86 4.5M 12% 77% 4% 12K 12% Bloomberg and CNBC interviewed Eli Lilly CEO David Ricks on drug pricing and diabetes treatments.

GSK 85 3.1M 44% 78% 0% 15K 12% Interest in purchasing Pfizer’s Consumer Business and the CEOreshuffling 40% of the management team led GSK coverage.

J&J 125 4.9M 4% 80% 1% 179K 20% On January 8, CEO Alex Gorsky stated that J&J should be worried about Amazon disrupting their business.

Sanofi 30 648K 20% 50% 7% 4K 4% Sanofi and Alnylam restructuring their deal for Alnylam’s pipeline drugs drove coverage throughout the conference.

Teva 44 1.3M 68% 7% 9% 2K 9% Teva’s Board of Directors cutting their salaries in half and eliminating 40 manufacturing sites drove coverage on January 10.

Celgene 111 4.3M 32% 71% 15% 5K 16% Celgene’s intent to acquire Impact Biomedicines generated a peak in coverage on the first day of the conference.

Prominence Mix Tone Mix

*JPM18 = 705 stories captured from top tier media list

88


Twitter Volume Comparison Tone Mix Engagement by Day

Competitive Social Media Performance

*JPM18 = 31,683 Twitter posts

Company Post Count % RT Unique Authors Post Eng Potential

ReachShare of JPM18* Highlights

Merck 292 78% 228 1.1K 3.1M 1% Merck’s social media conversation and engagement were in large part driven by owned content and Fox/CNBC promotions of scheduled interviews with Ken Frazier.

Pfizer 325 67% 257 740 3.3M 1%Regeneron announced a new genetic sequencing consortium in which Pfizer has been tabbed as a partner and will co-fund the work with a planned completion by

2022.

Allergan 201 60% 148 522 1.4M 1%Statements made by Brent Saunders on drug pricing and the strength of Botox’s performance were positively received. He was the driving force behind over half of

Allergan’s social media content.

Eli Lilly 189 72% 131 464 2.3M 1%Dave Ricks’s discussion of drug pricing, tax reform, and more with Meg Tirrell of CNBC was prominently discussed. His comments on drug pricing were met with

some criticism, particularly for Diabetes.

GSK 273 82% 206 731 2.8M 1%Emma Walmsley shared her thoughts on being the first female CEO to lead a major

pharmaceutical company in an interview with Meg Tirrell, and in widely shared pieces from STAT and Business Insider.

J&J 1,138 82% 587 2.9K 10.7M 4%J&J led in total posts, largely due to owned content launched throughout the event.

J&J shared 41 #ChampionsOfScience posts (a series on innovation and advancement) garnering nearly 500 retweets.

Sanofi 319 55% 213 519 2.6M 1%The announcement that Sanofi and Alnylam will restructure their rare disease alliance drove the social conversation, with most of the focus on Alnylam re-

acquiring the rights to patisiran.

Teva 123 46% 93 142 500K 0%The “Teva Turnaround” was a prominent theme due to discussion of Kåre Schultz

comments on past mistakes and plans to cut over 14,000 jobs and cut back $3B in spend in a large scale restructure.

Celgene 560 68% 375 1,5K 5.2M 2%Celgene’s acquisition of Impact Biomedicines for $1.1B (up to $7B) accounted for

over 25% of their key metrics. The deal saw a mixed reception on social media, with some feeling Celgene overpaid.

99


Competitive Coverage by TopicIndustry Core Topics

• Merck saw the most original coverage of executives among competitors. CFO Robert Davis stating the company will continue to seek smaller acquisitions and CEO Kenneth Frazier’s interviews led to their lead in executive visibility during JPM18.

• Eli Lilly followed Merck largely due to Reuters coverage of CEO Dave Ricks stating the company’s cash would be used for business development opportunities, including early-stage M&A.

• GSK’s CEO Emma Walmsley was interviewed on potentially buying Pfizer’s consumer business, gender diversity, and shaking up the company’s leadership in television and print interviews.

• Pfizer and Sanofi’s lack of television interviews with its executive leadership contributed to relatively low executive visibility.

Spotlight on Executives• Celgene saw the most financial-oriented coverage

following the announcement they plan to purchase Impact Biomedicines, the release of their Q4 earnings, and shares falling after their 2018 revenue forecast was short of analysts’ expectations.

• GSK’s announcing they’re looking into purchasing Pfizer’s Consumer Business drove financial coverage for Pfizer and GSK alike.

• Merck’s financials were referenced frequently in coverage of CEO Kenneth Frazier’s comments on the impact of tax reform and Amazon’s potential disruption to the distribution of drugs.

• Allergan, Sanofi, and J&J received little financial coverage.

Spotlight on Financials• Pfizer saw the most coverage with an “innovation”

theme, however this coverage was largely negative, with coverage focusing on their announcement they are ending research into new Alzheimer’s and Parkinson’s drugs.

• Eli Lilly and J&J’s innovation-focused coverage referenced their respective histories in Alzheimer’s research in a widely syndicated Reuters story about Pfizer.

• Celgene CEO Mark Alles commented on the purchase of Impact Biomedicines in their innovation coverage. Merck CEO Kenneth Frazier discussed how tax reform will spark innovation in the future for pharmaceutical companies.

• Teva and Allergan saw no innovation-focused coverage.

Spotlight on Innovation

1010


Spotlight on Neuroscience• Neuroscience emerged as a theme at JPM18 among key competitors,

with 39 stories and 146 social media posts. • Pfizer led the industry in Neuroscience news coverage from the

conference, though 100% was negative.• Heading into the conference, news that Pfizer planned to end its Alzheimer’s and

Parkinson’s R&D program was widely covered in the new.. A Reuters piece with roughly 20 pickups was primarily focused on Pfizer, but also mentioned Eli Lilly and GSK for their involvement in the Dementia Discovery Fund, as well as J&J for its partnership with Pfizer in an unsuccessful clinical trail.

• Negative coverage continued on the first day of the conference, including a scathing opinion piece by Michael Hiltzik for the Los Angeles Times in which he criticizes Pfizer for cutting this program while pocketing money from the new corporate tax cuts.

• The social media conversation around Pfizer from the conference was largely focused on this topic as well. Andy Lee (@andy_d_lee) of NeuroInitiative suggested Pfizer Neuro experts looking for a new job apply to his Parkinson’s program. Taking a more positive tone, @BioWorld and @pharmaphorum each noted Pfizer’s plan to assist research through a venture fund instead.

• J&J saw the most neuroscience related social media content, though largely due to retweets of their owned posts. • The most successful posts from the @JNJInnovation handle discussed their 15 new

collaborations, and the potential use of AI to analyze speech patterns of Alzheimer’s patients in an effort to detect the disease earlier.

• J&J Alzheimer’s R&D was mentioned in reporting on Pfizer’s end to its own program, but did not see any primary coverage. A piece carried in the Wall Street Journal and Fox Business discussing industry efforts to fight Alzheimer’s in spite of recent setbacks made reference to J&J’s research collaboration with the University of Pennsylvania, as well as initiatives from Eli Lilly, Merck, Takeda, and Roche.

• Merck is mentioned in Pfizer coverage as a company that will continue to invest in Alzheimer’s and Parkinson’s R&D.

News and Social SOV

Stories by Week

Prominence of Coverage Tone of Coverage

1111


Other Notable Conference Themes

• Bill Gates’ keynote address at JPM18 received widespread praise and social coverage:• Social media conversations praised Gates’ emphasis on impact over earnings, although he was

careful to note that impact and earnings are not mutually exclusive. Many posts featured excerpts from his speech, highlighting the theme of working together to improve the health and well-being of the world, instead of viewing health as a zero sum game.

• His speech elicited 11 news stories, many of which noted Gates’ message to drug makers that the private sector can benefit from pursuing breakthroughs in global health.

• Pictures of attendees and presenters wearing Pink Socks and using the #pinksocks saw 1,000 social posts:• “Pink Socks,” a movement started by Nick Adkins of ReelDX, were worn, pictured, and mentioned in

social posts throughout the conference. The socks are meant to represent what many people believe is an urgent need for disrupting healthcare from the ground up.

• JPM’s “Michael Problem” was a consistent criticism of the conference:• While largely ignored in news media (with a few exceptions), the fact that more men named Michael

than female CEOs gave presentations at the J.P. Morgan Healthcare Conference drew critical social posts from users who dubbed the phenomenon the “Michael Problem.”

• In addition to pointing out the Michael Problem, social posts dove further into the issue of gender inequality, pointing out that men represented more than 75% of the JPM18 speakers overall and the pharmaceutical industry has a gender inclusion problem among its executive leadership.

1212


Merck at JPM18 – News Media Performance

• Merck saw 70 stories over the course of JPM18. This ranked 6th among major pharma companies tracked. • With nearly three quarters of coverage being passing mentions, coverage

was also overwhelmingly neutral. • Among stories with a primary or secondary focus, 79% was positive. • 66% of stories mentioned a Merck executive, 53% referenced financials, and

16% of stories discussed Merck innovation.

• Substantive coverage was largely driven by interviews with Merck executives:• Interviews of CEO Ken Frazier featured his outlook on the company’s future,

noting that the Trump administration’s tax reform agenda helps Merck compete better with ex-US competitors and has been been helpful for patients accessing affordable drugs. In particular, his interview with Maria Bartiromo covered these themes, as well as the “Amazon effect” and the increasing incidence of Alzheimer’s.

• Merck was also mentioned in coverage of Pfizer’s exit from Alzheimer’sresearch and development. Merck R&D chief Roger Perlmutter said in an interview that they understand the space is particularly challenging, but the company believes it is important to “remain in the game.”

• Passing mentions focused on:• Industry-oriented coverage of tax reform, which often asserted that the

changes are positive for pharma and that not much will change in the short term as far as research and development.

• Other coverage reported that executives are expecting M&A activity could pick up on the heels of tax reform passing, as already evident by Celgene’s agreement to purchase Impact Biosciences. The article references that M&A’s on a large scale such as Merck’s acquisition of Schering Plough in 2009 had become rare, but implies this may change.

Story Count and Engagement

Stories and Engagement by Day

Prominence of Coverage Tone of Coverage

1313


Merck at JPM18 – Social Media Performance

• Merck JPM18 Twitter volume remained consistent YOY, with 292 in 2018 making up 3% of all Merck Twitter content during the review period and 1% of all JPM18 posts. • However, post engagement, potential reach, and tone all saw positive

gains in 2018.• Unique author count also increased from 192 to 248, which expanded the

base for engagement and potential reach.• Engagement more than doubled in 2018 to 1,093. This was primarily due

to additional posts from Merck’s Twitter handle, and posts from prominent authors such as Maria Bartiromo. The large following (comparatively) for each contributed to above average engagement per post. Competitors saw a similar trend of prominent media anchors (in several cases, the same ones)/pharma news outlets driving engagement, or content creation through owned channels.

• Merck authored content used positive language such as: “excited to be at,” “continued innovation,” and “improving global health.” Retweets of this content carried much of the positive coverage for the brand.

• Excluding owned content, only 60 original tweets were created mentioning the Merck brand. Of those, only a handful were organic consumer commentary. The vast majority of coverage consisted of interview promotion, content recap/transcripts, or links to larger articles covering key topics (rebates, pricing, tax reform implications) discussed by Merck CEO Ken Frazier.

• Event related posts only represented 3% of total Merck mentions during the reporting period, however they peaked at 14% on the 8th and 9th. This did contribute to a minor uptick in overall daily brand volumes, but as a point of comparison, a single stock/market tweetgenerated more volume (660 retweets) about the brand than the JPM18 contribution.

Conference and Merck Post Volume YOY Merck JPM by Engagement YOY

Merck JPM18 Posts and Engagement by Day

Merck JPM Posts by Tone YOY Post Volume by Engagement Value

1414


Merck Quality Score

• The average Quality Score for Merck during JPM18 was 25.• 4% of coverage had a high quality score of 40+.• No stories had a negative QS.

• Stories with the highest QS included:• Tax Plan Puts American Companies On An Even Playing Field:

Merck CEO(Fox Business) 01/09/18, QS:45.0Topics: Positive, Merck Executive, Merck Innovation

• Amazon Could Be Helpful To Us: Merck CEO(Fox Business) 01/09/18, QS:45.0Topics: Positive, Merck Executive, Merck Innovation

• Merck CEO Interview(Fox Business Mornings With Maria) 01/09/18, QS:45.0Topics: Positive, Merck Executive, Merck Innovation

• Stories with the lowest QS did not have any common themes:• Friday Five - The JP Morgan Debrief

(FirstWordPharma) 01/11/17, QS: 25.0Tags: Neutral, Merck Executive

• The Health 202: Here's One Legal and Political Battle You Didn't Expect(Washington Post) 01/10/17, QS: 20.0Tags: Neutral, Merck

• Biotech ETF Leaks Cash As Hopes For More M&A Fizzle(Bloomberg News) 01/16/18, QS:25.0Tags: Neutral, Merck Executive

*See page 18 for definitions/methodology for Quality Score.

1515


Interviews with Ken Frazier drove primary coverage in the top 10 sources with the most engagement.

• Fox Business was the leading source in terms of engagement, with a combined 2,264 shares during the review period. Maria Bartiromo’s interview with Ken Frazier drove this coverage, with additional reporting focused on his statements about Alzheimer’s, Amazon drug sales, and the US tax overhaul.

• Bartiromo’s interview with Frazier was also cited by CNBC, another top source, as a highlight of the conference. A separate Frazier interview conducted by CNBC’s Meg Tirrell was the primary driver of coverage from this source. Along with the interview itself, CNBC posted additional reporting which focused on Frazier’s comments on drug rebates, as well as his praise of the US tax plan for allowing Merck to invest more heavily in R&D.

• FiercePharma covered Frazier’s statements on drug pricing during a Q&A session.

Merck Influencers: Top Outlets & Social Authors

News Media Top Sources Social Media Top Authors

Top twitter authors primarily consisted of CNBC/FOX affiliates, financial advisors, news and journalist handles.

• Two authors tweeted about Merck coverage YOY: Brecht Vanneste (Self proclaimed “active in the pharmaceutical industry”), and Jodi Gralnick (CNBC producer). While both garnered enough likes and retweets to push engagement, their potential unique audience was low.

• Tweets from Fox Business News’ Maria Bartiromo generated the most engagement, despite only posting twice. In promotion of JPM18 coverage, she shared a lineup of speakers/participants, which included “@Merck ceo.”

• Vista Partners, live tweeted from the event to present its services. They shared coverage and quotes from the event, helping consumers ‘stay informed.’ Despite a follower base of 52K, and series of 4 posts, few users interacted with the content (2.75 avg. eng/post).

• FiercePharma shared their “need to know” JPM18 round up article, and commentary on drug pricing from a Q&A session with CEO Ken Frazier.

1616


Interactive Dashboards

Analytics Dashboards

• JP Morgan Healthcare 2018 Conference: Merck• JP Morgan Healthcare 2018

Conference: Competitive View

1717


Scoring MethodologySource Capture & Filtering

Sources: 120+ top tier sourcesMedia Type: Online sites, newspapers, magazines,

broadcast (radio & television)

Scoring

Method: Human-scoredTonality: 7-point scaleProminence: Primary, secondary, mention

Measures

Audience: Audience ReachedStory Count: Article in print, online, or broadcast

segment; each wire pickup counts as a separate story

Tonality DetailsStories are scored on a 7-point tonality scale. Analysts follow a disciplined methodology for scoring tonality unless other client direction is provided.

VERY POSITIVE: Includes articles containing positive commentary above and beyond typical positive reporting. This could include, raving endorsements, references to superlatives (e.g., “best product on the market”), reporting that something is breaking records or is unprecedented.

POSITIVE: Includes proactive announcements without detracting commentary. Or other articles that have only positive commentary.

SOMEWHAT POSITIVE: Includes articles about a positive topic that has limited detracting commentary, or an article that is primarily neutral but includes one or two references to something positive.

NEUTRAL: Passing mentions or other instances where there is not enough context to determine if the story is positive or negative. Stories in which positive/negative tonality elements balance each other out.

SOMEWHAT NEGATIVE: Includes factual stories about a negative issue if the company is not at fault, or a negative story with some commentary to offset the inherent negativity of an issue. Or an article that is primarily neutral but includes one or two references to something negative.

NEGATIVE: Includes articles about a negative issue without redeeming/balancing elements.

VERY NEGATIVE: Includes articles containing negative commentary above and beyond typical negative reporting. This could include stories containing rants or extremely negative statements.

Prominence DetailsProminence of a topic falls into one of the following categories:

PRIMARY: The topic was the focus of the coverage.

SECONDARY: The topic is not the primary focus of the coverage but was heavily mentioned. That is, the topic is featured in either an essential (albeit secondary) way or several times throughout the story.

MENTION: The topic is only casually referenced in the coverage, rather than being of primary or secondary focus.

1818


Scoring Methodology (cont’d)The Quality Score* is a single measure that is based on a number of scored article attributes, as outlined below. The Score ranges from -60 to +60. Here is how the score is calculated:

Attribute Description Point System Max. Weight

Prominence How prominently the company is mentioned (e.g., headline, first paragraph)

Primary = 15; Secondary = 10; Mention = 5 15

Executive Merck Executive referenced Yes = 5 5

Financials Merck Financials referenced Yes = 5 5

Innovation Merck Innovation referenced Yes = 5 5

Max. Raw Score:30

Attribute Description Point System Max. Weight

Tonality Positive/negative score along 7-point scale; neutral obtains 1 multiplier (not zero)

+2.0, +1.5, +1.25, +1.0, -1.25, -1.5, -2.0 +2.0 to -2.0

Max. Story QS: 60

*Prototype example of “Quality Score,” a Dow Jones like index, computed as the weighted score of attributes that may have the most impact.

1919


Scoring Methodology (cont’d)TopicsMerck Themes: Executives, Financials, Innovation, Neuroscience

Pfizer Themes: Executives, Financials, Innovation, Neuroscience, Hospira

AstraZeneca Themes: Executives, Financials, Innovation, MedImmune

Allergan Themes: Executives, Financials, Innovation

AbbVie Themes: Executives, Financials, Innovation, Pharmacyclics

Amgen Themes: Executives, Financials, Innovation

Bayer Themes: Executives, Financials, Innovation

Eli Lilly Themes: Executives, Financials, Innovation, Neuroscience

Gilead Themes: Executives, Financials, Innovation

GlaxoSmithKline Themes: Executives, Financials, Innovation, Neuroscience

Johnson & Johnson Themes: Executives, Financials, Innovation, Neuroscience, Janssen

Novartis Themes: Executives, Financials, Innovation, Neuroscience, Alcon, Sandoz

Perrigo Themes: Executives, Financials, Innovation

Roche Themes: Executives, Financials, Innovation, Neuroscience, Genentech

Sanofi Themes: Executives, Financials, Innovation, Genzyme

Takeda Themes: Executives, Financials, Innovation, Neuroscience

Teva Themes: Executives, Financials, Innovation

Bristol-Myers Squibb Themes: Executives, Financials, Innovation

Celgene Themes: Executives, Financials, Innovation

Shire Themes: Executives, Financials, Innovation

Mylan Themes: Executives, Financials, Innovation

ThemesExecutives Selected when C-suite level

official is quoted or interviewed

Financials Selected when financial performance or outlook is discussed

Innovation Selected when pipeline advancements are discussed

Neuroscience Selected when neuroscience related topics are discussed, particularly Alzheimer’s or Parkinson’s disease.

2020


General Mass MediaABC News AFPCBS News CNN Huffington Post NBC News NY Times NPRUSA Today TIME The AP Fox News MSNBC BuzzFeed Yahoo News

PharmaceuticalBioPharma DiveEndpoints NewsFierceBiotechFierceHealthFiercePharmaFiercePharmaManufacturingFiercePharmaMarketingFirstWordPharmaGenetic Engineering NewsHealthDay

HealioKaiser Health NewsMedCity NewsMedPage TodayMedscapemedwire NewsMedical Marketing MediaModern HealthcarePharmaceutical Business ReviewPharmaceutical CommercePharmaceutical ExecutivePharmaceutical ManufacturingPharmaLivePharmaphorumPharmaTimesSTAT

Top RegionalsArizona Republic Atlanta Journal-Constitution Austin American-Statesman Boston Globe Charlotte ObserverChicago Sun-Times Chicago Tribune Cleveland Plain Dealer

Dallas Morning News Denver Post Des Moines RegisterDetroit Free Press Fort Worth Star TelegramHouston Chronicle Los Angeles Times Miami Herald Milwaukee Journal Sentinel Minneapolis Star Tribune Newark Star-Ledger (nj.com) New York Daily News New York Post Orange County Register Orlando SentinelPhiladelphia InquirerSan Antonio Express-News San Francisco Chronicle San Jose Mercury News Seattle Times South Florida Sun-SentinelSt. Louis Post-DispatchTampa Bay Times U-T San Diego

InvestorsBarron’s Bloomberg/ BusinessWeek

Business Insider CNBC The EconomistFinancial Times Forbes Fortune Investor’s Business Daily Motley Fool Reuters Wall Street Journal Seeking Alpha Bloomberg TV Yahoo Finance

Public PolicyThe AtlanticDaily BeastForeign PolicyNational Journal Politico Politico EuropeRoll Call The Hill Vox Washington Post

Major Market Local TVWABC-TV

WCBS-TV WNBC-TV WNYW-TV KABC-TV KNBC-TV KCBS-TV KTTV-TV WBBM-TV WMAQ-TV WLS-TV WFLD-TV KYW-TV WCAU-TV WPVI-TV WTXF-TV KDFW-TV KTVT-TV KXAS-TV WFAA-TV

Source Capture & Filtering

Scoring Methodology (cont’d)

CONFERENCE MEDIA ANALYSIS January 2018 · 22 CONFERENCEMEDIAANALYSIS| January6 - 16, 2018 4...

Documents

Transcript of CONFERENCE MEDIA ANALYSIS January 2018 · 22 CONFERENCEMEDIAANALYSIS| January6 - 16, 2018 4...